DVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.51B

+6.42%

3.192

+42.51%

3.35B

+3.94%

2.459

+22.93%

3.45B

+2.09%

3.331

+12.9%

Estimates Revision

The market is revising Upward the revenue expectations for DaVita Inc. (DVA) for FY2025, with the revenue forecasts being adjusted by 0.72% over the past three months. During the same period, the stock price has changed by -11.81%.

Revenue Estimates for FY2025

Revise Upward

+0.72%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.12%

In Past 3 Month

Stock Price

Go Down

-11.81%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 139.00 USD with a low forecast of 133.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

1 Sell

Hold

Current: 0.000

Low

133.00

Averages

139.00

High

143.00

Current: 0.000

Low

133.00

Averages

139.00

High

143.00

Truist

David MacDonald

Hold

maintain

$128 -> $140

2026-01-05

New

Reason

Truist

David MacDonald

Price Target

$128 -> $140

2026-01-05

New

maintain

Hold

Reason

Truist analyst David MacDonald raised the firm's price target on DaVita to $140 from $128 and keeps a Hold rating on the shares. Despite the non-discretionary nature of the service and solid cash flow, improving volume trends remain critical amid a mixed environment marked by sluggish admissions, mortality, and missed treatments, the analyst tells investors in a research note.

TD Cowen

Gary Taylor

Hold

downgrade

$154 -> $133

2025-11-03

Reason

TD Cowen

Gary Taylor

Price Target

$154 -> $133

2025-11-03

downgrade

Hold

Reason

TD Cowen analyst Gary Taylor lowered the firm's price target on DaVita to $133 from $154 and keeps a Hold rating on the shares. The firm noted they missed 3Q25 EBIT by -10%, but they attribute a portion to Street mis-modeling while the recent pullback has Dthe shares shares looking more appealing, but a continued tepid volume outlook offsets upside.

Barclays

Equal Weight

maintain

$149 -> $143

2025-10-30

Reason

Barclays

Price Target

$149 -> $143

2025-10-30

maintain

Equal Weight

Reason

Barclays lowered the firm's price target on DaVita to $143 from $149 and keeps an Equal Weight rating on the shares post the Q3 report. The firm says an "unusual quarterly progression" drove a large disparity between DaVita's internal plan and Street estimates, resulting in a big headline miss but guidance reiteration.

Truist

David MacDonald

Hold

downgrade

$148 -> $140

2025-10-14

Reason

Truist

David MacDonald

Price Target

$148 -> $140

2025-10-14

downgrade

Hold

Reason

Truist analyst David MacDonald lowered the firm's price target on DaVita to $140 from $148 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.

BofA

analyst

Underperform

downgrade

$145 -> $140

2025-09-10

Reason

BofA

analyst

Price Target

$145 -> $140

2025-09-10

downgrade

Underperform

Reason

BofA lowered the firm's price target on DaVita to $140 from $145 and keeps an Underperform rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.

Truist

David MacDonald

Hold

downgrade

$164 -> $148

2025-08-08

Reason

Truist

David MacDonald

Price Target

$164 -> $148

2025-08-08

downgrade

Hold

Reason

Truist analyst David MacDonald lowered the firm's price target on DaVita to $148 from $164 and keeps a Hold rating on the shares. The firm is adjusting its estimates to reflect the company's Q2 results, raising its FY25 EPS view by 14c to $10.88 but cutting its price target to reflect a lower assumed multiple, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for DaVita Inc (DVA.N) is 9.30, compared to its 5-year average forward P/E of 12.83. For a more detailed relative valuation and DCF analysis to assess DaVita Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.83

Current PE

9.30

Overvalued PE

14.77

Undervalued PE

10.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.39

Current EV/EBITDA

7.78

Overvalued EV/EBITDA

10.24

Undervalued EV/EBITDA

8.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.84

Current PS

0.58

Overvalued PS

1.01

Undervalued PS

0.67

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 6939.07% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DVA News & Events

Events Timeline

No data

News

5.0

01-07NASDAQ.COM

Buffett Retires as CEO of Berkshire Hathaway; Abel Takes Over Leadership

5.0

01-07Fool

Buffett Steps Down, Ted Wechsler Takes Over $300 Billion Portfolio at Berkshire Hathaway

5.0

01-06Newsfilter

Tolion Appoints Gregory J. Moore to Enhance Global Expansion and Product Development

People Also Watch

Frequently Asked Questions

What is DaVita Inc (DVA) stock price today?

The current price of DVA is 111.45 USD — it has decreased -1.01 % in the last trading day.

What is DaVita Inc (DVA)'s business?

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.

What is the price predicton of DVA Stock?

What is DaVita Inc (DVA)'s revenue for the last quarter?

DaVita Inc revenue for the last quarter amounts to 3.42B USD, increased 4.80 % YoY.

What is DaVita Inc (DVA)'s earnings per share (EPS) for the last quarter?

DaVita Inc. EPS for the last quarter amounts to 2.04 USD, decreased -18.40 % YoY.

What changes have occurred in the market's expectations for DaVita Inc (DVA)'s fundamentals?

How many employees does DaVita Inc (DVA). have?

DaVita Inc (DVA) has 76000 emplpoyees as of January 10 2026.

What is DaVita Inc (DVA) market cap?

Today DVA has the market capitalization of 7.87B USD.